Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "antiviral agents" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Existing and future therapeutic options for hepatitis C virus infection.
Autorzy:
Bretner, Maria
Powiązania:
https://bibliotekanauki.pl/articles/1041462.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
antiviral agents
hepatitis C virus
Opis:
Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver failure worldwide. Chronic hepatitis C virus infection is treated with interferon-a (IFN-α), pegylated interferon-α (PEG-IFNα) alone or in combination with ribavirin; however, a significant fraction of patients either fail to respond or relapse after cessation of therapy. Efforts to identify and develop highly specific and potent HCV inhibitors have intensified recently. Each of the virally encoded replication enzymes has been a focus of studies as well as viral receptors and the host immune system. This review summarizes recent progress in the search for novel anti-HCV agents.
Źródło:
Acta Biochimica Polonica; 2005, 52, 1; 57-70
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Antiviral drug resistance rates among patients with chronic hepatitis B infection
Autorzy:
Özlük, Suat
Bayram, Yasemin
Özkaçmaz, Ayşe
Parlak, Mehmet
Özdemir, Ayşe
Aypak, Cenk
Powiązania:
https://bibliotekanauki.pl/articles/25102375.pdf
Data publikacji:
2023-06-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
antiviral agents
antiviral drug resistance
chronic hepatitis B
hepatitis B
Opis:
Introduction and aim. Chronic hepatitis B infection (CHB) affects millions of people around the world. Many clinicians find it challenging to choose therapeutic agents due to the mutations that occur in the hepatitis B virus (HBV) that cause drug resistance. Thus, the aim of this study was to determine the HBV resistance rates against the currently recommended first-line therapies in the region of our country where HBV prevalence is high. Material and methods. A total of 96 patients (56 men and 40 women) with HBV infection were enrolled in the study. The serum samples collected from those were analyzed with real-time polymerase chain reaction analysis followed by pyrosequencing (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) for drug resistance mutations associated with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. Results. HBV drug-resistance mutations were investigated in 80 treatment-naïve and 16 treatment-experienced patients (6 entecavir, 4 PEGylated-interferon, 4 tenofovir, 2 lamivudine). None of the HBV-DNA samples had mutations cause to drug resistance were detected in any codons regions that were analyzed. Conclusion. Antiviral resistance poses serious obstacles for clinicians in the treatment of CHB. Determining whether antiviral resistance exists in HBV is critical to choose the appropriate treatment agent.
Źródło:
European Journal of Clinical and Experimental Medicine; 2023, 2; 283-288
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies